Genetic and Dietary Predictors of Anti-platelet Response
Status:
Active, not recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This study will investigate differences in platelet aggregation under basal and
aspirin-treated conditions in American Indian and Alaska Native people who have extreme
levels (low and high) of n-3 polyunsaturated fatty acids (n-3 PUFAs, EPA and DHA) in red
blood cell membranes. The study will also determine whether or not platelet aggregation under
the different conditions is modified by CYP4A11, CYP4F2, CYP4F11, PEAR1, and ACTN1 gene
variation.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborators:
National Institute of General Medical Sciences (NIGMS) Oregon Health and Science University Southcentral Foundation University of Montana